| Literature DB >> 27362497 |
Kristian Traberg Larsen1, Tao Huang1, Mathias Ried-Larsen2,3, Lars Bo Andersen1,4, Malene Heidemann5, Niels Christian Møller1.
Abstract
The objective of the present study was to evaluate the effectiveness of a one-year multi-component immersive day-camp weight-loss intervention for children with overweight and obesity. The study design was a parallel-group randomized controlled trial. One hundred fifteen 11-13-year-old children with overweight and obesity were randomized into either: A six-week day-camp intervention arm focusing on increased physical activity, and healthy diet followed by a subsequent one-year family-based intervention, or a standard intervention arm consisting of one weekly exercise session for six weeks. Body mass index (BMI) was the primary outcome. BMI z-score, clustered cardiovascular risk z-score, and body composition were secondary outcomes. All outcomes were measured at baseline, six week-, and 52 week follow-up. After six weeks, children from the day-camp intervention arm had improved their BMI (-2.2 kg/m2 (95% CI -2.6 to -1.7, P<0.001)) and all secondary outcomes when compared to the children from the standard intervention arm. After 52 weeks, the day-camp intervention arm had a lower BMI (-1.2 kg/m2 (95% CI -1.8 to -0.5, P = 0.001)), and BMI z-score (-0.20 (95% CI -0.35 to -0.05, P = 0.008)), and clustered cardiovascular risk z-score (-0.23 (95% CI -0.37 to -0.08, P = 0.002)) compared to the standard intervention arm. No group differences were detected in body composition after 52 weeks. This study shows that the day-camp intervention arm is effective in reducing BMI and improving the metabolic health of children with overweight and obesity. However, the effects seem to be diminishing over time.Entities:
Mesh:
Year: 2016 PMID: 27362497 PMCID: PMC4928840 DOI: 10.1371/journal.pone.0157182
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of study constructs, the applied measurement methods, and the time points for the measurements.
| Construct | Method of measurement | Measurement time points | |||
|---|---|---|---|---|---|
| Primary outcome | |||||
| BMI | Height assessed without footwear and weight in underwear on a Soehnle 7700 Professional Medical electronic scale (Murrhardt, Germany). | √ | √ | √ | |
| Anthropometrics and body composition | The waist circumference was assessed between the lower costal margin and the iliac crest to the nearest 0.5 cm, at the end of a gentle expiration. Dual energy X-ray absorptiometry (DXA) was performed by an experienced operator on a GE Lunar Prodigy (GE Medical Systems, Madison, WI), equipped with ENCORE software (version 12.3, Prodigy; Lunar Corp, Madison, WI). | √ | √ | √ | |
| Pubertal development | Pubertal development was assessed according to Tanner by self-evaluation to avoid violating the child’s intimacy. During self-evaluation the child privately estimated genitalia and breast development based on drawings (provided in | √ | √ | √ | |
| Cardiorespiratory fitness | By a progressive bicycle ergometer protocol (Monark Ergomedic 839e) until total exhaustion with indirect calorimetry (Innovision, AMIS 2001) and a Polar, RS800CX heart rate monitor. | √ | √ | √ | |
| Blood pressure | Blood pressure was assessed after 5 min of rest in a sitting position on the left upper arm with an automatic blood pressure monitor (Welch Allyn 300 series). | √ | √ | √ | |
| Blood measurements | After overnight fast, blood samples were drawn in the morning from the antecubital vein (right arm).The participants were lying supine during blood collection. Samples for serum were left in room temperature for 30 min. Samples for plasma (EDTA) were centrifuged as soon as possible, and they were placed in an icebox (within one hour) before centrifugation. All samples were centrifuged at 2500G for 10 min. Then the samples were stored at -80°C until analysis.Insulin was analyzed with AlphaLISA® immunoassay kits (PerkinElmer, Waltham, MA, USA) in 384 microplate platform. The serum glucose and lipids were measured with Architect C16000 clinical chemistry analyzer (Abbott Diagnostics, Illinois, USA). Glucose was analyzed using Hexokinase/G-6-PDH methods. HDL-C and LDL-C were measured using homogenous enzymatic colorimetric analysis. TC and TG were analyzed using enzymatic colorimetric analysis. | √ | √ | √ | |
| Parent’s lifestyle, ethnicity, and socio-economic status | By letter distributed questionnaire. Parents socio-economic status was based on the mothers highest educational level. | √ | √ | ||
| Physical activity | Assessed by hip-worn accelerometer Actigraph GT3X+ for ten consecutive days for habitual physical activity, for seven consecutive days for estimated activity level during the day camp (SCIA only), and for two sessions of exercise sessions for the SIA. | √ | √ | √ | |
| Food intake during camp | Assessed by food registration for two entire days. For every meal the child had their food weighed and photographed for subsequent analyses of energy and nutrition content, with Winfood 4.0 software, by trained and qualified personal. | √ | |||
Baseline characteristics.
| Total | Day Camp Intervention Arm | Standard Intervention Arm | P-values | |
|---|---|---|---|---|
| 106 (44.3) | 55 (47.3) | 51 (41.2) | C2 0.528 | |
| (n = 106) | (n = 55) | (n = 51) | ||
| 12.0 (0.4) | 12.0 (0.4) | 12.0 (0.4) | TT 0.344 | |
| 66.0 | 70.6 | 61.8 | C2 0.465 | |
| (n = 99) | (n = 52) | (n = 47) | ||
| | 11 / 14 | 7 / 8 | 4 / 6 | |
| | 18 / 21 | 11 / 13 | 7 / 8 | |
| | 12 / 23 | 6 / 7 | 6 / 16 | C2 0.076 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 4 / 0 | 3 / 0 | 1 / 0 | |
| | 24 / 4 | 13 / 2 | 11 / 2 | |
| | 17 / 37 | 9 / 18 | 8 / 19 | |
| | 2 / 15 | 1 / 9 | 1 / 6 | |
| | 0 / 3 | 0 / 0 | 0 / 3 | C2 0.339 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 156.0 (6.1) | 156.4 (6.6) | 155.5 (5.7) | TT 0.465 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 60.1 (53.9–65.5) | 61.3 (55.4–66.2) | 59.2 (52.4–62.9) | WR 0.117 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 24.3 (22.6–26.9) | 24.8 (22.8–27.1) | 23.9 (22.5–26.9) | WR 0.215 |
| (n = 106) | (n = 55) | (n = 51) | ||
| Mean (SD) | 1.94 (0.49) | 1.99 (0.46) | 1.87 (0.51) | TT 0.209 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 0.00 (0.62) | 0.12 (0.62) | -0.13 (0.60) | TT 0.044 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 83.0 (78.5–88.0) | 84.5 (80.5–89.0) | 81.5 (77.0–85.0) | WR 0.015 |
| (n = 104) | (n = 55) | (n = 49) | ||
| | 39.3 (6.2) | 39.5 (6.2) | 39.2 (6.2) | TT 0.810 |
| (n = 104) | (n = 55) | (n = 49) | ||
| | 47.8 (43.8–52.8) | 47.9 (44.5–53.8) | 47.0 (42.6–52.5) | WR 0.587 |
| (n = 104) | (n = 55) | (n = 49) | ||
| | 34.0 (30.6–36.3) | 34.8 (31.0–37.3) | 33.3 (30.0–35.2) | WR 0.055 |
| (n = 86) | (n = 80) | (n = 75) | ||
| | 34.0 (5.3) | 33.2 (5.4) | 34.8 (5.1) | TT 0.167 |
| (n = 104) | (n = 55) | (n = 49) | ||
| | 105.4 (8.1) | 106.6 (7.6) | 103.9 (8.5) | TT 0.088 |
| (n = 106) | (n = 55) | (n = 51) | ||
| | 9 | 3 | 6 | |
| | 67 | 36 | 31 | |
| | 30 | 16 | 14 | C2 0.507 |
| (n = 99) | (n = 54) | (n = 45) | ||
| | 3.27 (2.91–3.78) | 3.29 (2.95–3.90) | 3.18 (2.87–3.54) | WR 0.307 |
| (n = 99) | (n = 54) | (n = 45) | ||
| | 0.80 (0.59–1.21) | 0.80 (0.66–1.21) | 0.83 (0.57–1.14) | WR 0.516 |
| (n = 93) | (n = 52) | (n = 41) | ||
| | 5.03 (4.79–5.26) | 5.09 (4.86–5.33) | 4.97 (4.71–5.12) | WR 0.048 |
| (n = 92) | (n = 52) | (n = 40) | ||
| | 8.90 (6.39–12.50) | 9.35 (6.56–12.33) | 8.19 (6.33–13.41) | WR 0.654 |
| (n = 99) | (n = 54) | (n = 45) | ||
| | 4.23 (3.81–4.71) | 4.38 (3.90–4.81) | 3.93 (3.70–4.48) | WR 0.030 |
| (n = 99) | (n = 54) | (n = 45) | ||
| | 1.30 (1.14–1.48) | 1.32 (1.14–1.50) | 1.27 (1.11–1.47) | WR 0.576 |
| (n = 92) | (n = 52) | (n = 40) | ||
| | 2.00 (1.40–2.89) | 2.06 (1.46–2.89) | 1.66 (1.32–2.86) | WR 0.498 |
Means with standard deviations (SD) for normal distributed data and medians with inter quartile ranges (IQR) for non-normal distributed data are presented for each intervention arm and for the total sample. To test for group differences at baseline T-tests for normal distributed data, Wilcoxon rank-sum tests for non-normal distributed data, and Chi2 tests for categorical data were applied.
TT = T test.
C2 = Chi2 test.
WR = Wilcoxon rank-sum test.
* = P<0.05.
† = Based on the mothers’ education level.
‡ = There is significant difference between year groups.
BMI = body mass index. CCR = Clustered cardiovascular risk. HDL = high-density lipoprotein. HOMA-IR = homeostasis model analysis—insulin resistance.
Fig 1Flow of participants.
The intervention effects on BMI, BMI z-score, and body composition.
| Mean (SD), N = SIA/DCIA | Within group change at 6 weeks | Within group change at 52 weeks | Difference in change at 6 weeks | Difference in change at 52 weeks | |||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Baseline | 6 weeks | 52 weeks | Mean(95% CI) | Mean(95% CI) | Mean(95% CI) | P-value | Mean(95% CI) | P-value |
| N = 51/55 | N = 43/51 | N = 38/48 | |||||||
| | 24.5 (2.9) | 24.2 (3.1) | 24.8 (3.7) | -0.2 (-0.5 to 0.1) | 0.1 (-0.4 to 0.6) | -2.2 (-2.6 to -1.7) | <0.001 | -1.2 (-1.8 to -0.5) | 0.001 |
| | 25.2 (2.8) | 22.7 (2.6) | 23.8 (3.1) | -2.4 (-2.7 to -2.1) | -1.1 (-1.5 to -0.6) | ||||
| N = 51/55 | N = 43/51 | N = 38/48 | |||||||
| | 1.87 (0.51) | 1.77 (0.56) | 1.73 (0.66) | -0.08 (-0.15 to -0.01) | -0.19 (-0.30 to -0.08) | -0.44 (-0.54 to -0.34) | <0.001 | -0.20 (-0.35 to -0.05) | 0.008 |
| | 1.99 (0.46) | 1.45 (0.58) | 1.53 (0.63) | -0.52 (-0.59 to -0.45) | -0.39 (-0.49 to -0.29) | ||||
| N = 49/55 | N = 44/50 | N = 39/47 | |||||||
| | 39.2 (6.2) | 38.1 (7.0) | 37.3 (8.1) | -1.3 (-2.3 to -0.4) | -2.0 (-3.4 to -0.7) | -5.1 (-6.4 to -3.8) | <0.001 | -1.8 (-3.7 to 0.1) | 0.062 |
| | 39.5 (6.2) | 32.9 (7.4) | 34.4 (7.3) | -6.5 (-7.3 to -5.6) | -3.8 (-5.1 to -2.6) | ||||
| N = 49/55 | N = 44/50 | N = 39/47 | |||||||
| | 47.5 (7.3) | 45.6 (8.0) | 44.2 (9.9) | -1.8 (-3.2 to -0.5) | -3.0 (-4.8 to -1.1) | -7.2 (-9.0 to -5.3) | <0.001 | -2.1 (-4.6 to 0.4) | 0.093 |
| | 48.0 (7.1) | 38.9 (9.8) | 41.5 (9.6) | -9.0 (-10.2 to -7.8) | -5.1 (-6.8 to -3.4) | ||||
| N = 49/55 | N = 44/50 | N = 39/47 | |||||||
| | 33.2 (4.2) | 34.3 (3.9) | 37.3 (4.7) | 1.0 (0.4 to 1.6) | 3.7 (3.1 to 4.4) | -0.5 (-1.3 to 0.8) | 0.276 | -0.5 (-1.3 to 0.8) | 0.289 |
| | 34.7 (4.1) | 35.2 (4.4) | 38.1 (5.1) | 0.6 (-0.0 to 1.1) | 3.2 (2.7 to 3.8) | ||||
BMI, BMI z-score, percentage body fat and percentage abdominal fat at baseline and difference in group changes after 6 and 52 weeks using two-sided linear mixed effects models for repeated measures.
* = P<0.05.
The intervention effects on clustered cardiovascular risk and the contributing components.
| Mean (SD), N (SIA/DCIA) | Within group change at 6 weeks | Within group change at 52 weeks | Difference in change at 6 weeks | Difference in change at 52 weeks | |||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Baseline | 6 weeks | 52 weeks | Mean(95% CI) | Mean(95% CI) | Mean(95% CI) | P-value | Mean(95% CI) | P-value |
| N = 51/55 | N = 50/55 | N = 49/55 | |||||||
| | -0.13 (0.60) | 0.14 (0.71) | 0.04 (0.70) | 0.28 (0.17 to 0.38) | 0.19 (0.08 to 0.29) | -0.41 (-0.55 to -0.26) | <0.001 | -0.23 (-0.37 to -0.08) | 0.002 |
| | 0.12 (0.62) | -0.01 (0.57) | 0.08 (0.59) | -0.13 (-0.23 to 0.03) | -0.04 (-0.14 to 0.06) | ||||
| N = 41/45 | N = 35/45 | N = 32/43 | |||||||
| | 34.8 (5.1) | 35.9 (6.0) | 35.4 (5.5) | 1.0 (-0.4 to 2.4) | 0.2 (-1.3 to 1.7) | 3.1 (1.2 to 5.0) | 0.001 | 1.0 (-0.9 to 2.9) | 0.301 |
| | 33.2 (5.4) | 38.1 (6.9) | 35.4 (6.0) | 4.1 (2.8 to 5.3) | 1.2 (-0.0 to 2.5) | ||||
| N = 49/55 | N = 44/51 | N = 38/47 | |||||||
| | 103.9 (8.5) | 103.1 (7.7) | 105.0 (8.6) | -1.0 (-2.9 to 0.9) | 0.8 (-1.2 to 2.8) | -5.4 (-7.9 to -2.8) | <0.001 | -3.1 (-5.7 to -0.4) | 0.026 |
| | 106.6 (7.6) | 100.1 (6.9) | 103.9 (6.3) | -6.3 (-8.1 to -4.6) | -2.2 (-4.0 to -0.4) | ||||
| N = 51/55 | N = 43/51 | N = 38/48 | |||||||
| | 82.4 (8.1) | 82.0 (8.8) | 79.8 (9.0) | -0.3 (-1.8 to 1.1) | -2.7 (-4.6 to -0.8) | -5.4 (-7.4 to -3.5) | <0.001 | -2.0 (-4.5 to 0.6) | 0.132 |
| | 85.5 (7.8) | 79.4 (8.6) | 79.8 (8.3) | -5.8 (-7.1 to -4.4) | -4.7 (-6.4 to -3.0) | ||||
| N = 45/54 | N = 36/47 | N = 32/42 | |||||||
| | 0.90 (0.44) | 1.01 (0.70) | 0.87 (0.52) | 1.10 (0.93 to 1.28) | 0.98 (0.83 to 1.15) | 0.85 (0.69 to 1.05) | 0.126 | 1.02 (0.82 to 1.26) | 0.886 |
| | 1.03 (0.60) | 0.89 (0.40) | 1.00 (0.50) | 0.93 (0.81 to 1.07) | 0.99 (0.86 to 1.15) | ||||
| N = 45/54 | N = 36/47 | N = 32/42 | |||||||
| | 3.3 (0.7) | 3.4 (0.8) | 3.4 (1.1) | 0.07 (-0.10 to 0.23) | 0.10 (-0.07 to 0.27) | -0.30 (-0.52 to -0.07) | 0.009 | -0.58 (-0.81 to -0.35) | <0.001 |
| | 3.5 (0.8) | 3.2 (0.6) | 3.0 (0.7) | -0.23 (-0.38 to -0.08) | -0.48 (-0.63 to -0.32) | ||||
| N = 45/54 | N = 36/47 | N = 32/42 | |||||||
| | 2.7 (2.5) | 2.5 (1.8) | 2.4 (1.6) | 0.96 (0.77 to 1.19) | 0.93 (0.75 to 1.16) | 0.75 (0.57 to 1.00) | 0.054 | 1.01 (0.75 to 1.32) | 0.969 |
| | 2.4 (1.4) | 1.7 (0.8) | 2.0 (0.7) | 0.72 (0.60 to 0.87) | 0.93 (0.77 to 1.12) | ||||
Clustered cardiovascular risk z-score (CCR z-score) and the contributing components at baseline and difference in group changes after 6 and 52 weeks using linear mixed effects models for repeated measures.
* = P-value <0.05.
† = results presented in ratios after log transformation and back transformation (due to non-normal distributed data).